Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

December 17, 2025
4 min

Dana-Farber

1

Dana-Farber's adult and pediatric stem cell transplant programs received a +1 performance score from CIBMTR, indicating exceptional outcomes.
2

This marks the sixth consecutive year for the adult program and the second for the pediatric program to achieve a +1 score.
3

Dana-Farber is one of only eight centers in the U.S. identified as overperforming in the CIBMTR analysis of 176 transplant centers.
4

The pediatric program is the only dedicated program in the U.S. to exceed the expected one-year survival rate for donor stem cell transplants.
5

The CIBMTR analysis adjusts for various factors to ensure fair evaluation of each center's outcomes based on patient complexity.

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

1

2

3

4

5

Original Source(s)

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Related Content

Dana-Farber Research News 07.01.2026

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis